First New York Securities’s Argos Therapeutics, Inc. ARGS Stock Holding History

First New York Securities’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-20	Closed	-$3.56K	–	632
2015 Q1	$3.56K	Buy	+20	New	+$3.48K	﹤0.01%	327

Other funds holding ARGS

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Caisse de Depot et Placement du Quebec (CDPQ) Montreal, Quebec, Canada $70.2B AUM 30.95% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tredje AP-fonden Se-111 91 Stockholm, Sweden $22.1B AUM 41.68% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PSI

Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return

Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $34B AUM 40.73% 1-Year Est. Return

First New York Securities's ARGS Position: Q2 2015 in Review

First New York Securities sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2015, closing a stake of 20 shares — an estimated $3.56K sold.

First New York Securities first reported a position in ARGS in Q1 2015 and held it in 1 quarter. The position peaked at $3.56K in Q1 2015. 21 funds tracked by Wall St. Rank hold ARGS as of Q2 2015.

First New York Securities reported no remaining Argos Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
First New York Securities sold 20 Argos Therapeutics, Inc. shares in Q2 2015, an estimated $3.56K.
First New York Securities first reported a position in Argos Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
First New York Securities's Argos Therapeutics, Inc. position peaked at $3.56K in Q1 2015.
21 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2015.

Based on First New York Securities's 13F filing for Q2 2015, filed 30 Jul 2015.